Haumaitre / Cros

Heterogeneity of Pancreatic Tumourigenesis (PATH)

L’équipe se concentre sur le décryptage des mécanismes cellulaires et moléculaires impliqués dans la séquence inflammation-cancer dans le pancréas, ainsi que sur l’hétérogénéité de l’initiation et de la progression des néoplasmes pancréatiques, avec pour objectif d’approfondir nos connaissances et de proposer de nouvelles stratégies thérapeutiques pour ces tumeurs au pronostic très sombre.

1. Identifying the factors and molecular mechanisms of pancreatic inflammation and the development of precancerous lesions:
   We discovered that the absence of the transcription factor Hnf1b causes pancreatitis and facilitates tumorigenesis (Quilichini, Cell Mol Gastroenterol Hepatol, 2019). We have elucidated the aetiology and pathophysiology of the MODY5/HNF1B pancreatic phenotype in a mouse model of the human disease (Quilichini, J Pathol, 2021). We are studying the factors involved in acinar ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) (Marstrand-Daucé, Int J Mol Sci, 2023). We are exploring the role of Hnf1b in the initiation of intraductal papillary mucinous neoplasms (IPMN) (Ligue Contre le Cancer, 2022; Fondation ARC Fellowship).
2. The role of metabolic syndrome (MS) and obesity in the development of precancerous lesions:
   We have demonstrated that fatty pancreas is associated with higher BMI, fibrosis and PanIN, using quantitative MRI elastography (Rebours, Sci Rep, 2018). We are studying the mechanisms involved and developing MRI sequences to improve the early detection of pancreatic lesions in patients (PAIR Programme, 2018).
3. Heterogeneity and plasticity of pancreatic neoplasms: We studied the inter-tumour heterogeneity of tumour cells (Puleo, Gastroenterology, 2018; Hilmi, Eur J Cancer, 2020; Zao, Clin Cancer Res, 2021), of the stroma (Neuzillet, J Pathol, 2019, 2022) and their clinical impact using artificial intelligence models (Saillard, Nat Commun, 2023). To stratify patients, we have developed biomarkers predictive of sensitivity to gemcitabine, a key drug in pancreatic adenocarcinoma (Raffenne, Cancers, 2019; Piquemal, Cancers, 2020; Bachet, Clin Cancer Res, 2020; Nicolle, Ann Oncol, 2021; Trans Oncol, 2022; J Clin Oncol, 2023).
   Our objectives are:
   (i) to understand the biological basis of the morphological heterogeneity of pancreatic adenocarcinomas and neuroendocrine tumours through multi-omic spatial profiling (INCa PRTK, 2020; PL-BIO, 2023; MIC, 2022; NRFT, 2022),
   (ii) to develop innovative biomarkers based on AI and transcriptomics to predict the risk of progression of pre-neoplastic lesions (ARC Foundation, 2023; Ligue Contre le Cancer, 2019),
   (iii) better understand and improve the action of radionuclide-based therapies in neuroendocrine tumours (RHU OPERANDI, 2022).
4. Orexin system in inflammation and cancer:
   Orexin receptors are abnormally expressed in digestive inflammation and multiple cancers (Couvineau et al., 2018-2022). We have demonstrated that orexin induces an anti-inflammatory effect in inflammatory bowel disease, pancreatitis, multiple sclerosis, metabolic syndrome (Messal N, BBA Mol Basis Dis., 2018; Becquet, J Neuroinflammation, 2019) and reduces fat mass (Blais et al., PLOS One, 2017). We have identified that orexin induces SHP2-dependent apoptosis involving the Gq protein, leading to anti-tumour effects (Dayot S, Oncotarget, 2018; Voisin T, Front Oncol, 2022; Gratio, Cytometry, 2023). We have developed a synthetic antibody that mimics the anti-tumour role of orexin in pancreatic adenocarcinoma and other cancers (European Sanofi iAward, 2020-2021, patent).